[Comment] Targeting OX40: rocatinlimab—a novel therapy for atopic dermatitis

00:00 - 25 Nov 2025

Atopic dermatitis presents with heterogeneous clinical features and complex immune dysregulation. While primarily driven by a T helper 2 (Th2)-skewed response, other T cell subsets and pathways, including the OX40-pathway, contribute to disease pathogenesis.1,2 Rocatinlimab, a fully human monoclonal antibody targeting the OX40 receptor (OX40R) on activated T cells, inhibits pathogenic OX40R+ T cells, offering a novel approach to rebalance T cell populations and reduce inflammation.3 In this Comment we outline and review the results of two phase 3 trials (ROCKET-IGNITE [IGNITE] and ROCKET-HORIZON [HORIZON]), published in The Lancet by Emma Guttmann-Yaski and colleagues, evaluating rocatinlimab in adult patients with atopic dermatitis.